<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYPROHEPTADINE HYDROCHLORIDE - cyproheptadine hydrochloride syrup </strong><br>Actavis Mid Atlantic LLC<br></p></div>
<h1>Cyproheptadine Hydrochloride Syrup
(Cyproheptadine Hydrochloride Oral Solution, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s01"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s02"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">Each 5 mL (one teaspoonful) contains:</span> Cyproheptadine Hydrochloride 2 mg</p>
<p><span class="Bold">Inactive Ingredients:</span> Alcohol 5%, citric acid, D&amp;C Yellow #10, flavors, purified water, sodium citrate, sorbic acid (0.1% as preservative) and sucrose syrup.</p>
<p>Cyproheptadine HCI is an antihistaminic and antiserotonergic agent. Cyproheptadine hydrochloride is a white to slightly yellowish, crystalline solid, with a molecular weight of 350.89, which is slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform and practically insoluble in ether. It is the sesquihydrate of 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine hydrochloride. The molecular formula of the anhydrous salt is C<span class="Sub">21</span>H<span class="Sub">21</span>N•HCl and the structural formula of the anhydrous salt is:</p>
<p><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=54686520-506f-7765-7220-436f736d6963&amp;name=Structural_Formula.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s03"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s04"></a><a name="section-4"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics and Metabolism:</span> After a single 4 mg oral dose of <span class="Sup">14</span>C-labeled cyproheptadine HCI in normal subjects, given as tablets or syrup, 2-20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12-20 mg daily doses of cyproheptadine syrup. The principal metabolite found in human urine has been  identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.<br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s05"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Perennial and <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span><br><span class="product-label-link" type="condition" conceptid="4305500" conceptname="Vasomotor rhinitis">Vasomotor rhinitis</span><br><span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">Allergic conjunctivitis</span> due to inhalant allergens and foods<br>Mild, uncomplicated allergic skin manifestations of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span><br>Amelioration of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to blood or plasma<br><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Cold</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><br>Dermatographism</p>
<p>As therapy for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> <span class="Italics">adjunctive </span>to epinephrine and other standard measures after the acute manifestations have been controlled.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s06"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">Newborn or Premature Infants: </span>This drug should <span class="Italics">not </span>be used in newborn or premature infants.</p>
<p><span class="Bold">Nursing Mothers: </span>Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.</p>
<p><span class="Bold">Other Conditions:</span><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to cyproheptadine and other drugs of similar chemical structure<br>Monoamine oxidase inhibitor therapy (see <a href="#s10">Drug Interactions</a>)<br>Angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span><br>Stenosing <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span><br>Symptomatic <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span><br><span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">Bladder neck obstruction</span><br>Pyloroduodenal obstruction<br>Elderly, debilitated patients</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s07"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold">Children:</span> Overdosage of antihistamines, particularly in infants and children, may produce <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation.</p>
<p><span class="Bold">CNS Depressants:</span> Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.</p>
<p><span class="Bold">Activities Requiring Mental Alertness: </span>Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.</p>
<p>Antihistamines are more likely to cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in elderly patients.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s08"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<span class="Bold">General:</span> Cyproheptadine has an atropine-like action and, therefore, should be used with caution in patients with:<br><dl>
<dt> 
</dt>
<dd>History of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> </dd>
<dt> 
</dt>
<dd><span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span> </dd>
<dt> 
</dt>
<dd><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> </dd>
<dt> 
</dt>
<dd>Cardiovascular disease </dd>
<dt> 
</dt>
<dd><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </dd>
</dl>
<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s09"></a><a name="section-9"></a><p></p>
<p class="First"><span class="Bold">Information for Patients: </span>Antihistamines may diminish mental alertness; conversely, particularly in the young child, they may occasionally produce excitation. Patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a car or operating machinery.<br></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s10"></a><a name="section-10"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines. Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s11"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>: Long-term carcinogenic studies have not been done with cyproheptadine. Cyproheptadine had no effect on fertility in a two-litter study in rats or a two-generation study in mice at about 10 times the human dose. Cyproheptadine did not produce chromosome damage in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or fibroblasts <span class="Italics">in vitro;</span> high doses (10<span class="Sup">-4</span>M) were cytotoxic. Cyproheptadine did not have any mutagenic effect in the Ames microbial mutagen test; concentrations of above 500 mcg/plate inhibited bacterial growth.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s12"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:</span> Pregnancy Category B. Reproduction studies have been performed in rabbits, mice and rats at oral or subcutaneous doses up to 32 times the maximum recommended human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to cyproheptadine. Cyproheptadine has been shown to be fetotoxic in rats when given by intraperitoneal injection in doses four times the maximum recommended human oral dose. Two studies in pregnant women, however, have not shown that cyproheptadine increases the risk of abnormalities when administered during the first, second and third trimesters of pregnancy. No teratogenic effects were observed in any of the newborns. Nevertheless, because the studies in humans cannot rule out the possibility of harm, cyproheptadine should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s13"></a><a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from cyproheptadine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see <a href="#s06">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s14"></a><a name="section-14"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> Safety and effectiveness in pediatric patients below the age of two years have not been established. (See <a href="#s06">CONTRAINDICATIONS, Newborn or Premature Infants</a>, and <a href="#s07">WARNINGS, Children</a>.)</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s15"></a><a name="section-15"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions which have been reported with the use of antihistamines are as follows:</p>
<p><span class="Bold">Central Nervous System:</span> Sedation and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> (often transient), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, disturbed coordination, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, excitation, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="434889" conceptname="Dissociative disorder">hysteria</span>, faintness.</p>
<p><span class="Bold">Integumentary: </span>Allergic manifestation of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, excessive perspiration, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="Bold">Special Senses:</span> Acute <span class="product-label-link" type="condition" conceptid="74052" conceptname="Labyrinthitis">labyrinthitis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>.</p>
<p><span class="Bold">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Digestive System:</span> Dryness of mouth, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>.</p>
<p><span class="Bold">Genitourinary: </span><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>, difficult urination, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, early menses.</p>
<p><span class="Bold">Respiratory:</span> Dryness of nose and throat, thickening of bronchial secretions, tightness of chest and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>.</p>
<p><span class="Bold">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>/<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s16"></a><a name="section-16"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Antihistamine overdosage reactions may vary from central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to stimulation especially in children. Also, atropine-like signs and symptoms (<span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>; fixed, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, etc.) as well as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> may occur.</p>
<p><span class="Italics">If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has not occurred spontaneously</span>, the patient should be induced to vomit with syrup of ipecac.</p>
<p><span class="Italics">If the patient is unable to vomit</span>, perform gastric lavage followed by activated charcoal. Isotonic or 1/2 isotonic saline is the lavage of choice. Precautions against <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> must be taken especially in infants and children. When life-threatening CNS signs and symptoms are present, intravenous physostigmine salicylate may be considered. Dosage and frequency of administration are dependent on age, clinical response and recurrence after response. (See package circulars for physostigmine products.)</p>
<p><span class="Italics">Saline cathartics,</span> as milk of magnesia, by osmosis draw water into the bowel and, therefore, are valuable for their action in rapid dilution of bowel content.</p>
<p><span class="Italics">Stimulants </span>should <span class="Italics">not</span> be used. Vasopressors may be used to treat <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>The oral LD<span class="Sub">50</span> of cyproheptadine is 123 mg/kg, and 295 mg/kg in the mouse and rat, respectively.<br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s17"></a><a name="section-17"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.</p>
<p>Although intended primarily for administration to children, the syrup is also used for administration to adults who cannot swallow tablets.</p>
<p><span class="Bold">Children:</span> The total daily dosage for children may be calculated on the basis of body weight or body area using approximately 0.25 mg/kg/day (0.11 mg/lb/day) or 8 mg per square meter of body surface (8 mg/m<span class="Sup">2</span>).</p>
<p><span class="Italics">Age 2 to 6 years: </span>The usual dose is 2 mg (one teaspoonful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 12 mg a day.</p>
<p><span class="Italics">Age 7 to 14 years: </span>The usual dose is 4 mg (two teaspoonsful) two or three times a day, adjusted as necessary to the size and response of the patient. The dose is not to exceed 16 mg a day.</p>
<p><span class="Bold">Adults:</span> The total daily dose for adults should not exceed 0.5 mg/kg/day (0.23 mg/lb/day). The therapeutic range is 4 to 20 mg a day, with the majority of patients requiring 12 to 16 mg a day. An occasional patient may require as much as 32 mg a day for adequate relief. It is suggested that dosage be initiated with 4 mg (two teaspoonsful) three times a day and adjusted according to the size and response of the patient.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s18"></a><a name="section-18"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Cyproheptadine Hydrochloride Syrup (Cyproheptadine Hydrochloride Oral Solution, USP, 2 mg/5 mL) in a yellow, mint-flavored vehicle, is supplied in a pint (473 mL) container.</p>
<p>Store at 20°-25°C (68°-77°F) excursion permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP.</p>
<p><span class="Bold">Manufactured by:</span><br>Lyne Laboratories, Inc.<br>Brockton, MA 02301</p>
<p><span class="Bold">Distributed by:</span><br>Actavis Mid Atlantic LLC                                    FORM NO. 1400<br>1877 Kawai Road                                                         VC108865<br>Lincolnton, NC 28092 USA</p>
<p>REV. 10/10</p>
<br><p><br></p>
<p><span class="Bold">EACH 5 mL (ONE TEASPOONFUL) CONTAINS:</span> Cyproheptadine Hydrochloride 2 mg, Alcohol 5%, Sorbic Acid 0.1% added as preservative.</p>
<p><span class="Bold">USUAL DOSAGE:</span> See accompanying package insert.<br>Store at 20°-25°C (68°-77°F) excursion permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].<br><br>Dispense in a tight, light-resistant container as defined in the USP.<br><br>Manufactured by:<br>Lyne Laboratories, Inc.<br>Brockton, MA 02301<br><br>Distributed by:<br>Actavis Mid Atlantic LLC<br>1877 Kawai Road<br>Lincolnton, NC 28092 USA<br><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s19"></a><a name="section-19"></a><p></p>
<p class="First"><br><br><br><span class="Bold">actavis</span></p>
<p>NDC 0472-<span class="Bold">1400</span>-16</p>
<p><span class="Bold">Rx Only</span></p>
<span class="Bold">Cyproheptadine<br>Hydrochloride<br>Syrup</span><br><br>(Cyproheptadine Hydrochloride<br>Oral Solution, USP)<br><br><span class="Bold">2 mg/5 mL<br><br>One Pint (473mL)<br><br></span><div class="Figure"><img alt="Product Display Panel" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=54686520-506f-7765-7220-436f736d6963&amp;name=Product_Display_Panel.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYPROHEPTADINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">cyproheptadine hydrochloride syrup</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0472-1400</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYPROHEPTADINE HYDROCHLORIDE</strong> (CYPROHEPTADINE) </td>
<td class="formItem">CYPROHEPTADINE HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">MINT (MINT) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0472-1400-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040668</td>
<td class="formItem">07/31/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Mid Atlantic LLC
							(809515898)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Lyne Laboratories, Inc. (053510459)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lyne Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">053510459</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1f18da82-08a9-408e-9ffa-7808b996cffc</div>
<div>Set id: 54686520-506f-7765-7220-436f736d6963</div>
<div>Version: 3</div>
<div>Effective Time: 20110909</div>
</div>
</div> <div class="DistributorName">Actavis Mid Atlantic LLC</div></p>
</body></html>
